▼ Safinamide (Xadago - Zambon S.p.A) is a monoamine-oxidase B (MAO-B) inhibitor licensed as add-on therapy for people with idiopathic Parkinson's disease who are experiencing motor fluctuations with levodopa.¹ Currently there is no cure for Parkinson's disease and drugs are used to reduce motor symptoms and improve daily activities.²,³ Here, we review the evidence for this MAO-B inhibitor.
No takes yet. Share an insight, caveat, or question.
Baum et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: